Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA vs TECHNIVIE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Technivie is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that inhibits HCV RNA replication and virion assembly. Paritaprevir is an NS3/4A serine protease inhibitor that prevents cleavage of the HCV polyprotein. Ritonavir is a pharmacokinetic enhancer that inhibits CYP3A-mediated metabolism of paritaprevir, increasing its plasma levels.
Relief of moderate to moderately severe pain
Treatment of chronic hepatitis C virus (HCV) genotype 4 infection in adult patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) in combination with ribavirin
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
TECHNIVIE (ombitasvir, paritaprevir, and ritonavir) is administered orally as two fixed-dose combination tablets (each containing ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg) taken once daily in the morning with food, in combination with dasabuvir (250 mg twice daily with food) for genotype 1b or with ribavirin for genotype 1a.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life approximately 40 hours, supporting once-daily dosing
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Ombitasvir: Primarily metabolized by amide hydrolysis followed by oxidative metabolism. Paritaprevir: Primarily metabolized by CYP3A4. Ritonavir: Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Biliary/fecal (majority, >90% as unchanged drug); renal (<1%)
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
>99.9%, primarily to albumin and alpha-1-acid glycoprotein
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
0.2 L/kg, indicating distribution largely confined to plasma and extracellular fluid
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Oral: not determined; absorption is rapid with Tmax of 4-5 hours post-dose
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
No dose adjustment of TECHNIVIE is required for patients with any degree of renal impairment, including those on dialysis. However, if used with ribavirin, refer to ribavirin dosing adjustments for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
TECHNIVIE is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A).
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Safety and efficacy in pediatric patients below 18 years of age have not been established; therefore, no dosing recommendations are available.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
No dose adjustment of TECHNIVIE is required in elderly patients. Clinical studies included patients aged 65 and older, with no overall differences in safety or efficacy observed.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Boxed Warning: Risk of Hepatitis B Virus (HBV) Reactivation. HBV reactivation has been reported in patients co-infected with HCV and HBV who were treated with direct-acting antivirals for HCV. Some cases resulted in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection before starting Technivie. Monitor patients for HBV reactivation during treatment and post-treatment follow-up.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
HBV reactivation: Screen for HBV before initiation.,Hepatic decompensation/hepatic failure in patients with cirrhosis: Discontinue if signs of hepatic decompensation occur.,Increases in transaminases: Monitor hepatic function, especially during first 4 weeks of therapy.,Use with estrogen-containing contraceptives: May increase ALT levels; discontinue estrogens if ALT elevation occurs.,Drug interactions: Technivie is a CYP3A4 inhibitor; consider dose adjustments of sensitive CYP3A4 substrates.,Ribavirin: Use with caution in patients with creatinine clearance <50 m L/min.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Severe hepatic impairment (Child-Pugh B or C) or decompensated cirrhosis.,Concomitant use with drugs that are strong CYP3A inducers (e.g., rifampin, St. John's wort).,Known hypersensitivity to ombitasvir, paritaprevir, ritonavir, or any excipients.,Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, ergot derivatives, lovastatin, simvastatin, etc.).,Concomitant use with ethinyl estradiol-containing contraceptives.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Take with food to increase absorption (increase paritaprevir exposure). No specific dietary restrictions. Avoid grapefruit products? Not reported for TECHNIVIE, but ritonavir has interactions with grapefruit; generally not recommended due to potential CYP3A4 interaction.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Avoid in pregnancy unless benefit outweighs risk.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No data on presence in human milk; risk to infant cannot be excluded. M/P ratio unknown.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
No dose adjustment required based on pharmacokinetic changes in pregnancy; monitor closely.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
TECHNIVIE (ombitasvir/paritaprevir/ritonavir) is indicated for chronic hepatitis C genotype 4 without cirrhosis or with compensated cirrhosis (Child-Pugh A). Avoid in decompensated cirrhosis (Child-Pugh B or C) due to risk of hepatic decompensation. Ritonavir is a strong CYP3A4 inhibitor; check for drug interactions. Monitor hepatic function closely, especially in patients with cirrhosis.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
Take with food to improve absorption and reduce gastrointestinal side effects.,Do not stop taking this medication without consulting your doctor.,Inform your doctor of all medications you take, including over-the-counter and herbal supplements, due to significant drug interactions.,Report symptoms of liver problems: yellowing of skin/eyes, dark urine, abdominal pain, or nausea/vomiting.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA vs TECHNIVIE, answered by our medical review team.
ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. TECHNIVIE is a Direct-acting antiviral that works by Technivie is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that inhibits HCV RNA replication and virion assembly. Paritaprevir is an NS3/4A serine protease inhibitor that prevents cleavage of the HCV polyprotein. Ritonavir is a pharmacokinetic enhancer that inhibits CYP3A-mediated metabolism of paritaprevir, increasing its plasma levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA and TECHNIVIE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. The standard adult dose of TECHNIVIE is: TECHNIVIE (ombitasvir, paritaprevir, and ritonavir) is administered orally as two fixed-dose combination tablets (each containing ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg) taken once daily in the morning with food, in combination with dasabuvir (250 mg twice daily with food) for genotype 1b or with ribavirin for genotype 1a.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA and TECHNIVIE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . TECHNIVIE is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Avoid in pregnancy unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.